Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 3/20 | 0.48 |
| ▸ | PPARG | P37231 | 5/20 | 0.44 |
| ▸ | MET | P08581 | 1/20 | 0.42 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.41 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.41 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 5/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
| ▸ | KLK1 | P06870 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | WNT1 | P04628 | 2/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14587790 | 0.93 | KLKB1 (0.44) | KLKB1PPARGCACNA1GCACNA1HCACNA1I | |
| SCHEMBL14587777 | 0.92 | KLKB1 (0.44) | KLKB1PPARGCACNA1GCACNA1HCACNA1I | |
| SCHEMBL14587679 | 0.91 | PPARG (0.42) | KLKB1PPARGCACNA1GCACNA1HCACNA1I | |
| SCHEMBL14587778 | 0.91 | PPARG (0.52) | KLKB1PPARGMETCACNA1GCACNA1H | |
| SCHEMBL14587673 | 0.90 | PPARG (0.42) | KLKB1PPARGCACNA1GCACNA1HCACNA1I | |
| SCHEMBL14587664 | 0.89 | PPARG (0.42) | KLKB1PPARGCACNA1GCACNA1HCACNA1I | |
| SCHEMBL14587788 | 0.88 | PPARG (0.42) | KLKB1PPARGCACNA1GCACNA1HCACNA1I | |
| SCHEMBL14301499 | 0.83 | PPARG (0.46) | PPARGNTRK1RAB9A | |
| SCHEMBL14587697 | 0.83 | PPARG (0.46) | PPARGNTRK1RAB9A | |
| SCHEMBL14587669 | 0.82 | MERTK (0.48) | PPARGNTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | disclosed |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | PYGL, GYS2, AGL | KLKB1 3656/4885PPARG 706/4885MET 2931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.